Subscribe To
HZNP / Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates
HZNP News
By Zacks Investment Research
August 28, 2023
Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises more_horizontal
By Investopedia
August 28, 2023
Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger
Horizon Therapeutics (HZNP) shares jumped more than 5.5% in early trading Monday after the FTC said it would suspend its challenge to Amgen's (AMGN) a more_horizontal
By Zacks Investment Research
August 9, 2023
Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales
Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors bein more_horizontal
By Zacks Investment Research
August 8, 2023
Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics
The headline numbers for Horizon Therapeutics (HZNP) give insight into how the company performed in the quarter ended June 2023, but it may be worthwh more_horizontal
By Zacks Investment Research
August 8, 2023
Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates
Horizon Therapeutics (HZNP) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compare more_horizontal
By Zacks Investment Research
July 24, 2023
Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study
Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus. more_horizontal
By Zacks Investment Research
June 2, 2023
Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Seeking Alpha
May 29, 2023
Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon'
Amgen's stock has seen a further pullback since it announced an acquisition of Horizon Therapeutics in December. Shares are down by nearly a quarter a more_horizontal